# Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

> **NCT00193128** · PHASE1,PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 59 (actual)

## Conditions studied

- Esophagus Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Docetaxel
- **DRUG:** Capecitabine
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT00193128
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2008-02
- **Final completion:** 2009-01
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2021-11-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193128, "Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00193128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*